Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beazer Homes USA

CVS Health

iShares MSCI United Kingdom ETF

Lemonade

Whirlpool

Investors like keeping an eye on the famed investor Buffett. Here are seven more companies that could possibly become Warren Buffett stocks.

7 Stocks Warren Buffett Should Consider

Franklin Resources

Bank First Corp

Bristol-Myers

Cisco Systems

Illinois Tool Works

JPMorgan Chase & Co

Main Street Capital

Realty Income Corp

Oracle

ServisFirst Bancshares

W. P. Carey

Dividend Changes: December 19-25, 2020

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

Here's Why You Should Retain Stryker Stock Right Now

Stryker Corp. (NYSE:SYK) is in the right place with the right portfolio of products and the right strategy to continue its winning streak on Wall Street.

Stryker: Right Place, Right Time, Right Strategy

National Beverage

M.D.C. Holdings

NiSource

EchoStar

Disappointing jobless data combined with no stimulus and a pandemic continuing to reach grim records caused markets to trade largely mixed today. For investors looking to make the most of this market, the deep learning algorithms at Q.ai have crunched the data to give you a set of Top Buys.

Top Stocks To Buy Today As Poor Unemployment Data Impacts Trading

Stryker Corporation (SYK) Presents at Evercore ISI Third Annual HealthCONx Conference - Conference Call Transcript

Stryker Corp. said late Wednesday that its board of directors has declared a quarterly dividend of 63 cents a share, payable Jan. 29 to shareholders of record at the close of business on Dec. 31. That's a 9.6% dividend increase, the medical technology company said.

Stryker raises dividend by 9.6%

Abbott Labs

Graco

J & J Snack Foods

SEI Investments

AT&T

Waste Management

I was optimistic with my dividend growth predictions for the last two weeks of November. Notably, Sysco held their dividend steady and Tyson Foods – from which I had expected a double digit boost – only increased their dividend by 6%.

December Will Bring A Significant Dividend Increases From Medical Companies Abbott, Stryker

Kalamazoo, Michigan, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) (the “Company”) announced today that it has priced an offering of $600 million aggregate principal amount of its 0.600% Notes due 2023 (the “Notes”). Unless previously redeemed pursuant to their terms, the Notes will mature on December 1, 2023. The offering of the Notes is expected to settle on November 23, 2020, subject to the satisfaction of customary closing conditions.

Stryker announces pricing of $600 million senior notes offering

Kalamazoo, Michigan, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Thursday, December 3, 2020.

Stryker to participate in the 3rd Annual Evercore ISI HealthCONx Virtual Conference

Shares of Stryker Corp. (NYSE:SYK) are up 10.5% in 2020, but almost the entirety of that gain has been since the company reported earnings results at the end of October. Covid-19 has negatively impacted the company's operations for much of the year as elective surgeries were delayed due to the stress on the health care system.

Stryker Has a Bounce-Back Quarter

Colfax (CFX) arm DJO closes buyout of products/system related to ankle replacement and finger arthroplasty from Stryker, which will boost its product offerings in the reconstructive products space.

Colfax (CFX) Arm DJO Acquires Stryker's Extremity Products

Kalamazoo, Michigan, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that it has completed the previously announced acquisition of Wright Medical Group N.V. (NASDAQ: WMGI), a global medical device company focused on extremities and biologics.

Stryker completes acquisition of Wright Medical

Kalamazoo, Michigan, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that it intends to complete the acquisition of Wright Medical Group N.V. (NASDAQ: WMGI) by effectuating the mergers described in the tender offer statement on Schedule TO filed by Stryker B.V., an indirect, wholly owned subsidiary of Stryker, with the U.S. Securities and Exchange Commission on December 13, 2019, as amended. 

Stryker announces intention to complete acquisition of Wright Medical

Kalamazoo, Michigan, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol Myers Squibb, has been elected to its Board of Directors, effective December 1, 2020. 

Stryker elects Giovanni Caforio to Board of Directors

Kalamazoo, Michigan, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that all required regulatory approvals have been obtained for the previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI) by Stryker B.V., an indirect, wholly owned subsidiary of Stryker. The tender offer is being made pursuant to the purchase agreement, dated November 4, 2019, among Stryker, Stryker B.V. and Wright Medical.

Stryker announces receipt of all required regulatory approvals for proposed acquisition of Wright Medical

In this article we are going to use hedge fund sentiment as a tool and determine whether Stryker Corporation (NYSE:SYK) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds' picks don't beat the market 100% of the time, but their consensus picks have historically done very well and have outperformed the market after adjusting for risk.

Were Hedge Funds Right About Warming Up To Stryker Corporation (SYK)?

Stryker's (SYK) third-quarter earnings reflect strong segmental performance.

Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates

Stryker Corporation (SYK) CEO Kevin Lobo on Q3 2020 Results - Earnings Call Transcript

Kalamazoo, Michigan, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2020:

Stryker reports third quarter 2020 operating results

Kalamazoo, Michigan, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that Stryker B.V., an indirect, wholly owned subsidiary of Stryker, has extended the offering period of its previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI). The tender offer is being made pursuant to the purchase agreement, dated November 4, 2019, among Stryker, Stryker B.V. and Wright Medical.

Stryker extends cash tender offer for all outstanding shares of Wright Medical

Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stryker (SYK) Expected to Beat Earnings Estimates: Should You Buy?

Here's Why You Should Hold on to Stryker (SYK) Stock Now

Accuray

Intuitive Surgical

Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.

Robot-Assisted Surgery Gains Momentum Amid Coronavirus

AbbVie

Boston Scientific

Medtronic

Zimmer Biomet Hlds

While technology has been the engine that has driven stock market performance for some time now, increasingly we are seeing a seismic shift to health care among many portfolio managers, and with good reason.

News for Stryker Stock (SYK)